STATE OF OKLAHOMA

1st Session of the 57th Legislature (2019)

SENATE BILL NO. 1040 By: David

AS INTRODUCED

An Act relating to inborn metabolic disorders and other genetic or biochemical disorders; amending 63 O.S. 2011, Section 1-533, which relates to educational and newborn screening programs; adding certain disorder; providing that no cost shall be incurred except under certain condition; transferring certain duties to the State Department of Health and State Commissioner of Health; updating term; and providing an effective date.

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. AMENDATORY 63 O.S. 2011, Section 1-533, is amended to read as follows:

Section 1-533. A. The State ~~Board~~ Department of Health shall provide, pursuant to the provisions of Section 1-534 of this title as technologies and funds become available, an intensive educational and newborn screening program among physicians, hospitals, public health nurses, and the public concerning phenylketonuria, related inborn metabolic disorders, and other genetic or biochemical disorders including but not limited to spinal muscular atrophy, for which:

1. Newborn screening will provide early treatment and management opportunities that might not be available without screening; and

2. Treatment and management will prevent ~~mental retardation~~ intellectual disability and/or reduce infant morbidity and mortality.

B. This educational and newborn screening program shall include information about:

1. The nature of the diseases;

2. Examinations for the detection of the diseases in infancy; and

3. Follow-up measures to prevent the morbidity and mortality resulting from these diseases.

C. For purposes of this section, "phenylketonuria" means an inborn error of metabolism attributable to a deficiency of or a defect in phenylalanine hydroxylase, the enzyme that catalyzes the conversion of phenylalanine to tyrosine. The deficiency permits the accumulation of phenylalanine and its metabolic products in the body fluids. The deficiency can result in mental retardation (phenylpyruvic oligophrenia), neurologic manifestations (including hyperkinesia, epilepsy, and microcephaly), light pigmentation, and eczema. The disorder is transmitted as an autosomal recessive trait and can be treated by administration of a diet low in phenylalanine.

D. There shall be no cost associated with the screening unless there is a positive diagnosis.

E. The State ~~Board~~ Commissioner of Health shall promulgate any rules necessary to effectuate the provision of this section.

SECTION 2. This act shall become effective November 1, 2019.

57-1-397 DC 4/1/2019 8:16:56 AM